產(chǎn)品詳情
僅用于工業(yè)應(yīng)用或科學研究,不可用于人類或動物的臨床診斷或治療,非藥用. Bimekizumab (Anti-Human IL17A/IL-17F Recombinant Antibody) is a humanised monoclonal antibody, can selectively neutralises IL-17A and IL-17F. Both of them are pro-osteogenic with respect to human periosteum-derived cell (hPDC) differentiation. Thus Bimekizumab blocks the inflammation-driven osteogenic differentiation